Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
NCT06364423
Recruiting
Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers can modify a person's own immune cells (T cells) to target CD19. When these modified T cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: B-Cell Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic
Register for Updates
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California +28 locations
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343
Recruiting
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/25/2025
Locations: University of South Alabama, Mobile, Alabama +26 locations
Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Register for Updates
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398
Recruiting
A Phase 2 in Adult Subjects with Hereditary Angioedema
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Raffi Tachdjian, MD Inc, Santa Monica, California +18 locations
Conditions: Hereditary Angioedema (HAE)
Register for Updates
Deciphering the Genetic Architecture of Autoimmune Diseases
NCT06948110
Recruiting
Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors. But some diseases behave differently in people who are native to North and South America. Researchers want to know more about the gene changes and other factors that may cause autoimmune diseases among these people. This project will be based in Peru. Objective: To study how gene changes can lea... Read More
Gender:
ALL
Ages:
Between 18 years and 115 years
Trial Updated:
06/25/2025
Locations: National Human Genome Research Institute (NHGRI), Bethesda, Maryland +1 locations
Conditions: Autoimmune Diseases
Register for Updates
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
NCT00001281
Recruiting
We are studying virologic and/or immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-in... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/25/2025
Locations: Washington Hospital Center, Washington, District of Columbia +1 locations
Conditions: HIV, Immunodeficiencies, Infectious Diseases
Register for Updates
Lung Cancer Biomarkers and Screening
NCT00301119
Recruiting
RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer. PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/25/2025
Locations: NYU Cancer Institute at New York University Medical Center, New York, New York
Conditions: Lung Cancer
Register for Updates
Rod and Cone Mediated Function in Retinal Disease
NCT02617966
Recruiting
Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease. Objectives: To find out if how well a person sees in the dark can test the severity of retinal disease. To find out if this can help detect retinal disease and track it... Read More
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
06/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
Register for Updates
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
NCT04267848
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +1146 locations
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041
Recruiting
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +161 locations
Conditions: Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma
Register for Updates
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
NCT05549258
Recruiting
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/25/2025
Locations: UCSD Altman Clinical and Translational Research Institute Building, La Jolla, California +17 locations
Conditions: Neuromyelitis Optica Spectrum Disorder
Register for Updates
A Study of Changes in Heart Function and Blood Flow in People Receiving Anesthesia
NCT05954832
Recruiting
The purpose of this study is to understand changes in heart function (how the heart pumps blood) and blood flow in people who receive general anesthesia during surgery. The researchers are particularly interested in the heart function and blood flow changes in people who experience low blood pressure (hypotension) after receiving anesthesia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York
Conditions: Anesthesia
Register for Updates